Eylea biosimilar vial & PFS

Eylea biosimilar vial & PFS
Product Description

1.Completion of global clinical trials phase Ⅲ 
2. Completion of pre-submission meetings with advanced regulatory authorities
3. Available in Vial and PFS

Samchundang Pharm. Co., Ltd

  • KR
  • 2015
    On CPHI since
  • 4
    Certificates
  • 250 - 499
    Employees
Company types
Generics/Biosimilars Manufacturer
Primary activities
Pharmaceutical Company (generic finished products)
Specifications
  • Details
    1. Neovascular (wet) age-related macular degeneration (AMD)2. Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
    3. Visual impairment due to diabetic macular oedema (DME)
    4. Visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Samchundang Pharm. Co., Ltd

  • KR
  • 2015
    On CPHI since
  • 4
    Certificates
  • 250 - 499
    Employees
Company types
Generics/Biosimilars Manufacturer
Primary activities
Pharmaceutical Company (generic finished products)

More Products from Samchundang Pharm. Co., Ltd (4)